Literature DB >> 9259172

Can estrogens prevent neurodegeneration?

L S Schneider1, C E Finch.   

Abstract

Estrogen replacement therapy appears to have significant beneficial effects on cognition and mood in the elderly. In recent studies, its use has been associated with short term symptomatic cognitive improvement and with a decreased risk of (or a delay in) developing Alzheimer's disease (AD). Clinical reports are supported by substantial basic scientific evidence of the neuroprotective effects of estrogens. Their specific effects on dementia and cognitive impairment remain to be delineated. Ongoing randomised trials in AD will only provide information on the symptomatic effects of estrogen. Although basic research will progress, there is currently sufficient knowledge to promote active clinical research on the possible disease-modifying or neuroprotective effects of estrogens in the elderly.

Entities:  

Mesh:

Year:  1997        PMID: 9259172     DOI: 10.2165/00002512-199711020-00001

Source DB:  PubMed          Journal:  Drugs Aging        ISSN: 1170-229X            Impact factor:   4.271


  58 in total

1.  Oestrogen and mental state.

Authors:  G Fink; B E Sumner
Journal:  Nature       Date:  1996-09-26       Impact factor: 49.962

2.  Role of estrogens in peripheral and cerebral glucose utilization.

Authors:  J Bishop; J W Simpkins
Journal:  Rev Neurosci       Date:  1992 Apr-Jun       Impact factor: 4.353

3.  Estradiol in the striatum: effects on behavior and dopamine receptors but no evidence for membrane steroid receptors.

Authors:  E J Roy; D R Buyer; V A Licari
Journal:  Brain Res Bull       Date:  1990-08       Impact factor: 4.077

4.  Acute administration of high doses of estrogen increases glucose utilization throughout brain.

Authors:  H Namba; L Sokoloff
Journal:  Brain Res       Date:  1984-01-23       Impact factor: 3.252

5.  In vivo effects by estrone sulfate on the central nervous system-senile dementia (Alzheimer's type).

Authors:  H Honjo; Y Ogino; K Naitoh; M Urabe; J Kitawaki; J Yasuda; T Yamamoto; S Ishihara; H Okada; T Yonezawa
Journal:  J Steroid Biochem       Date:  1989       Impact factor: 4.292

6.  Effects of estrogen replacement therapy on response to tacrine in patients with Alzheimer's disease.

Authors:  L S Schneider; M R Farlow; V W Henderson; J M Pogoda
Journal:  Neurology       Date:  1996-06       Impact factor: 9.910

7.  Imipramine: effect of ovarian steroids on modifications in serotonin receptor binding.

Authors:  D A Kendall; G M Stancel; S J Enna
Journal:  Science       Date:  1981-03-13       Impact factor: 47.728

8.  The effects of aging and hormonal manipulation on amyloid precursor protein APP695 mRNA expression in the rat hippocampus.

Authors:  H M Chao; R L Spencer; M Frankfurt; B S McEwen
Journal:  J Neuroendocrinol       Date:  1994-10       Impact factor: 3.627

9.  Long-term estrogen replacement therapy in female patients with dementia of the Alzheimer type: 7 case reports.

Authors:  T Ohkura; K Isse; K Akazawa; M Hamamoto; Y Yaoi; N Hagino
Journal:  Dementia       Date:  1995 Mar-Apr

Review 10.  Rationale for the planned clinical trials with nerve growth factor in Alzheimer's disease.

Authors:  F Hefti; L S Schneider
Journal:  Psychiatr Dev       Date:  1989
View more
  3 in total

Review 1.  Tolerability profile of SERMs.

Authors:  D Agnusdei; N Iori
Journal:  J Endocrinol Invest       Date:  1999-09       Impact factor: 4.256

Review 2.  Raloxifene: a review of its use in postmenopausal osteoporosis.

Authors:  D Clemett; C M Spencer
Journal:  Drugs       Date:  2000-08       Impact factor: 9.546

3.  Increased risk of dementia in patients with osteoporosis: a population-based retrospective cohort analysis.

Authors:  Kuang-Hsi Chang; Chi-Jung Chung; Cheng-Li Lin; Fung-Chang Sung; Trong-Neng Wu; Chia-Hung Kao
Journal:  Age (Dordr)       Date:  2013-12-18
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.